[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 441,857,248
  • Shares Outstanding, K 1,766,793
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 16,870 M
  • EBITDA $ 25,856 M
  • 60-Month Beta 0.30
  • Price/Sales 7.16
  • Price/Cash Flow 16.37
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 24.27% (unch)
  • Historical Volatility 25.32%
  • IV Percentile 23%
  • IV Rank 34.53%
  • IV High 35.30% on 04/27/26
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 2) 3.89 (1.56%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 7,975
  • Volume Avg (30-Day) 20,234
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 295,882
  • Open Int (30-Day) 274,604
  • Expected Range 244.87 to 252.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $3.87
  • Number of Estimates 5
  • High Estimate $3.95
  • Low Estimate $3.84
  • Prior Year $1.86
  • Growth Rate Est. (year over year) +108.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
241.20 +3.13%
on 08/06/26
267.47 -7.00%
on 07/29/26
+0.68 (+0.27%)
since 07/10/26
3-Month
204.30 +21.76%
on 05/13/26
267.47 -7.00%
on 07/29/26
+40.90 (+19.68%)
since 05/12/26
52-Week
190.75 +30.41%
on 04/29/26
267.47 -7.00%
on 07/29/26
+50.12 (+25.23%)
since 08/12/25

Most Recent Stories

More News
Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

IRVINE, Calif. , Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced updates to Allergan Partner Privileges ® (APP), its customer portfolio loyalty program,...

ABBV : 248.76 (-0.53%)
MarketBeat Week in Review – 08/03 - 08/07

A weekly roundup of MarketBeat analysis covering earnings from AbbVie, AMD, Palantir, Meta, Reddit, SpaceX and others, plus upcoming CPI and PPI inflation data.

META : 578.85 (-3.38%)
ULTA : 531.89 (-1.75%)
SNDK : 1,344.29 (+5.76%)
RDDT : 153.45 (-1.75%)
RKLB : 81.17 (+1.45%)
ADM : 79.73 (-0.91%)
ABBV : 248.76 (-0.53%)
INBK : 29.20 (-0.27%)
BOOT : 160.74 (-3.05%)
MCD : 275.70 (+0.57%)
SPCX : 146.15 (+9.65%)
AMD : 482.93 (+1.82%)
The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

ABBV : 248.76 (-0.53%)
3 Cash-Producing Stocks for Long-Term Investors

3 Cash-Producing Stocks for Long-Term Investors

CPAY : 409.68 (+0.87%)
ABBV : 248.76 (-0.53%)
CRGY : 12.06 (-2.90%)
Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

IRVINE, Calif. , Aug. 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental...

ABBV : 248.76 (-0.53%)
The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure

As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).

JPM : 365.18 (+0.87%)
XOM : 159.75 (-0.03%)
JNJ : 260.86 (+0.41%)
SCHV : 35.19 (+0.80%)
MU : 911.29 (+4.92%)
BRK-B : N/A (N/A)
ABBV : 248.76 (-0.53%)
WMT : 116.01 (+2.43%)
What Are Wall Street Analysts' Target Price for AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

XLV : 168.44 (+0.26%)
$SPX : 7,748.50 (+0.26%)
ABBV : 248.76 (-0.53%)
AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

ABBV : 248.76 (-0.53%)
ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset

ABBV : 248.76 (-0.53%)
AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue

AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue

ABBV : 248.76 (-0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 255.30
2nd Resistance Point 252.69
1st Resistance Point 250.73
Last Price 248.76
1st Support Level 246.16
2nd Support Level 243.55
3rd Support Level 241.59

See More

52-Week High 267.47
Last Price 248.76
Fibonacci 61.8% 238.16
Fibonacci 50% 229.11
Fibonacci 38.2% 220.06
52-Week Low 190.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.